300233 Shandong Jincheng Pharmaceutical Group
- 16.72
- +0.14+0.84%
Shandong Jincheng Pharmaceutical Group News
Jincheng Pharmaceutical (300233.SZ): No TMA studies have been conducted
Gelonghui, May 17 | Jincheng Pharmaceutical (300233.SZ) said on the investor interactive platform that currently the company has not carried out TMA research, and in terms of technology, it can be produced using an enzymatic catalytic process in terms of synthesis.
Jincheng Pharmaceutical (300233.SZ): At present, the company has achieved industrial production and sales of glutathione, adenosylmethionine, PQQ, 4AA, nicotine and other products
Gelonghui, May 17, 丨 Jincheng Pharmaceutical (300233.SZ) said on the investor interactive platform that the company relied on years of deep experience in the field of chemistry and biosynthesis to build a “chemical+biosynthesis” dual synthesis research and production platform. The company focuses on the two major directions of biocatalysis and biosynthesis, focusing on enzymatic catalysis of chiral drugs and intermediates and biosynthetic products with high added value. At present, the company's products such as glutathione, adenosylmethionine, PQQ, 4AA, and nicotine have all been industrially produced and sold, which strongly supports the company's development.
Chinese Drug Regulator Gives Thumbs Up to Jincheng Pharmaceutical Unit's Application to Raise Cefadroxil Dry Suspension's Dosage
China's National Medical Products Administration approved the application of Shandong Jincheng Pharmaceutical Group's (SHE:300233) unit, Shanghai Jincheng Suzhi Pharmaceutical, to increase the dosage
Jincheng Pharmaceutical (300233.SZ): Cefadroxil dry suspension increases specifications and obtains approval notice for supplementary drug application
Gelonghui May 16 | Jincheng Pharmaceutical (300233.SZ) announced that Shanghai Jincheng Suzhi Pharmaceutical Co., Ltd. (hereinafter referred to as “Jincheng Suzhi”), a wholly-owned subsidiary of Shandong Jincheng Pharmaceutical Group Co., Ltd., received the “Drug Supplement Application Approval Notice” (certificate numbers: 2024B012112, 2024B012111, 2024B012110) for the dry suspension of cefadroxil issued by the State Drug Administration. The approval approved the addition of 5g (250mg/5ml) (based on C16H17N3O5S) and 7.5 g (500mg/5m) of this product
Jincheng Pharmaceutical (300233.SZ): Products such as glutathione, adenosylmethionine, PQQ, 4AA, and nicotine have all been industrialized
Gelonghui, May 10 | Jincheng Pharmaceutical (300233.SZ) said on the investor interactive platform that the company has been deeply involved in the field of synthetic biology for many years and has built a “chemical synthesis+biosynthesis” double synthesis research and production platform. The company's glutathione, adenosylmethionine, PQQ, 4AA, nicotine and other products have all been industrialized, forming a strong support for the company's development. The company focuses on the two major directions of biocatalysis and biosynthesis, focusing on enzymatic catalysis for chiral drugs and intermediates, and biosynthetic products with high added value. The company cooperates with many research institutes in technology development to accelerate the development and application of synthetic biology products
Jincheng Pharmaceutical (300233.SZ): The company also has two major R&D and production platforms for chemical synthesis and biosynthesis
Gelonghui, May 10 | Jincheng Pharmaceutical (300233.SZ) said on the investor interactive platform that the company also has two major R&D and production platforms for chemical synthesis and biosynthesis, which can achieve the organic combination of chemical synthesis and biosynthesis technology required for products such as APIs or pharmaceutical intermediates.
Jincheng Pharmaceutical (300233.SZ): The company has been deeply involved in the field of synthetic biology for many years
Gelonghui, May 8 | Jincheng Pharmaceutical (300233.SZ) said on the investor interactive platform that the company has been deeply involved in the field of synthetic biology for many years, has built an internationally leading synthetic biology industrialization platform, and has successfully implemented biosynthetic products such as glutathione, adenosine methionine, astaxanthin, PQQ, etc., as well as enzymatic catalytic products such as 4-AA and nicotine. The company has established close industry-university-research cooperation and platform co-construction with authoritative teams in the field, forming a complete synthetic biology industry chain from upstream R&D and pilot expansion to industrialization. Currently, many products are under research, and the company will actively promote product development progress as early as possible
The top-level file will be released soon! The concept of synthetic biology has risen to prominence, and the pace of industrial development has accelerated
Trillion racetrack
Earnings Troubles May Signal Larger Issues for Shandong Jincheng Pharmaceutical Group (SZSE:300233) Shareholders
Despite Shandong Jincheng Pharmaceutical Group Co., Ltd's (SZSE:300233) recent earnings report having lackluster headline numbers, the market responded positively. Sometimes, shareholders are willing
Can Mixed Fundamentals Have A Negative Impact on Shandong Jincheng Pharmaceutical Group Co., Ltd (SZSE:300233) Current Share Price Momentum?
Most readers would already be aware that Shandong Jincheng Pharmaceutical Group's (SZSE:300233) stock increased significantly by 13% over the past three months. But the company's key financial indic
Jincheng Pharmaceutical (300233.SZ): Application for marketing of chemical raw material oseltamivir phosphate approved
Zhitong Finance App News, Jincheng Pharmaceutical (300233.SZ) announced that Beijing Jincheng Taier Pharmaceutical Co., Ltd. (“Jincheng Taier”), a wholly-owned subsidiary of the company, has received a notice of approval for the marketing application of chemical raw materials issued by the State Drug Administration. The name of the chemical raw material is: oseltamivir phosphate. Oseltamivir phosphate is a precursor to its active metabolite (oseltamivir carboxylate), which is a selective influenza virus neuraminidase inhibitor.
Jincheng Pharmaceutical (300233.SZ) plans to distribute a cash dividend of 2 yuan for every 10 shares
Jincheng Pharmaceutical (300233.SZ) issued an implementation notice for the 2023 equity distribution. The company gave all shareholders every...
Jincheng Pharmaceutical (300233.SZ): Net profit of 82.97 million yuan in the first quarter increased 65.43% year-on-year
On April 24, Gelonghui Pharmaceutical (300233.SZ) released its first quarter report. Operating revenue was 930 million yuan, up 12.32% year on year, net profit of 82.97 million yuan, up 65.43% year on year, after deducting non-net profit of 80.31 million yuan, up 87.19% year on year, with basic earnings per share of 0.22 yuan.
Jincheng Pharmaceutical (300233.SZ): As of April 10, 2024, the number of shareholders of the company was 25,519
Gelonghui April 16 | Jincheng Pharmaceutical (300233.SZ) said on the investor interactive platform that as of April 10, 2024, the number of shareholders of the company was 25,519.
SDIC Securities: The logic of each segment of biomaneling is different, and there is a possibility that many tracks will break the game
According to the 2023 “Global and Chinese Plant Extract Industry Analysis Report”, the total scale of the global plant extraction industry will reach 30 billion US dollars in 2021, and the Chinese market is expected to reach 80 billion yuan in 2028. In the future, bio-manufacturing will replace plant extraction to reduce costs and increase efficiency, which is expected to open up the downstream market.
Jincheng Pharmaceutical (300233.SZ): Taking “Women's Health Technology” as one of the key development areas in the future
Gelonghui, April 9, 丨 Jincheng Pharmaceutical (300233.SZ) held a performance briefing on April 9, 2024 to discuss “If the company's participation in Dongfang Lue's VGX-3100 is approved for listing in the future, will the company actively participate in it?” The company replied that the company regards “women's health technology” as one of the key development areas in the future, and that if Dongfanglue VGX-3100 is approved for listing, the company will actively engage in negotiations with it.
Jincheng Pharmaceutical (300233.SZ): Medical nicotine is currently communicating with customers, sample grade products have been shipped
Gelonghui, April 9, 丨 Jincheng Pharmaceutical (300233.SZ) held a performance briefing on April 9, 2024 to discuss “Medical nicotine, what is the shipping situation in Jincheng?” The company replied that medical nicotine is currently communicating with the customer, that the sample-grade product has been shipped and is awaiting confirmation from the customer and the next cooperation plan.
Jincheng Pharmaceutical (300233.SZ): Currently, there are no sugar substitute products other than rebaudioside
Gelonghui April 9丨Jincheng Pharmaceutical (300233.SZ) held a performance briefing on April 9, 2024 to discuss “Does the company currently have plans for sugar replacement products?” The company replied that there are currently no sugar substitute products other than rebaudioside.
Jincheng Pharmaceutical (300233.SZ): 4AA currently produces normally according to design capacity, production and sales balance
Gelonghui, April 9, 丨 Jincheng Pharmaceutical (300233.SZ) held a performance briefing on April 9, 2024 to discuss “After introducing the 4AA project situation, can Huihai reverse its losses this year?” The company replied that 4AA currently produces normally according to the design capacity, production and sales are balanced, and Huihai sees a positive development trend from the first quarter.
Jincheng Pharmaceutical (300233.SZ): Produced glutathione raw materials are mainly used in downstream formulation production in China
Gelonghui, April 3 | Jincheng Pharmaceutical (300233.SZ) said on the investor interactive platform that the glutathione raw materials produced by the company are mainly used in downstream formulation production in China, and pyrroloquinoline quinone disodium salt is currently allowed to be used in beverages or solid beverages domestically.
Analysis
Price Target
No Data
